Journal of Clinical Lipidology
Volume 3, Issue 3 , Pages 179-186 , May 2009

Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia

  • Debra Kush, BSN, MBA

      Affiliations

    • Merck Research Laboratories, 126 East Lincoln Avenue, RY34A-218, Rahway, New Jersey, 07065 USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Hyo-Soo Kim, MD, PhD

      Affiliations

    • Seoul National University Hospital, Seoul, Korea
    • ,
  • Da Yi Hu, MD, FACC

      Affiliations

    • Peking University People's Hospital, Beijing, China
    • ,
  • Ji Liu, MA

      Affiliations

    • Merck Research Laboratories, 126 East Lincoln Avenue, RY34A-218, Rahway, New Jersey, 07065 USA
    • ,
  • Waheeda Sirah, BS

      Affiliations

    • Merck Research Laboratories, 126 East Lincoln Avenue, RY34A-218, Rahway, New Jersey, 07065 USA
    • ,
  • Aditi Sapre, PhD

      Affiliations

    • Merck Research Laboratories, 126 East Lincoln Avenue, RY34A-218, Rahway, New Jersey, 07065 USA
    • ,
  • Christine McCrary Sisk, BS

      Affiliations

    • Merck Research Laboratories, 126 East Lincoln Avenue, RY34A-218, Rahway, New Jersey, 07065 USA
    • ,
  • John F. Paolini, MD, PhD, FACC

      Affiliations

    • Merck Research Laboratories, 126 East Lincoln Avenue, RY34A-218, Rahway, New Jersey, 07065 USA
    • ,
  • Darbie Maccubbin, PhD

      Affiliations

    • Merck Research Laboratories, 126 East Lincoln Avenue, RY34A-218, Rahway, New Jersey, 07065 USA

Received 9 December 2008 ,Accepted 20 April 2009.

References 

  1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection . Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report. Circulation. 2002;106:3143–3421
  2. Abbott Pharmaceuticals. Niaspan (niacin extended-release tablets) US prescribing information. Copyright 2005. Available at: http://www.rxabbott.com/pdf/niaspantablet.pdf.
  3. The coronary drug project. JAMA. 1972;221:918
  4. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  5. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-bind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  6. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–381
  7. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  8. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642–650
  9. Abbott Laboratories. NIASPAN® (niacin extended-release tablets) US prescribing information. Copyright 2005. Available at: http://www.niaspan.com/pdf/niaspan_pi_ r1.pdf. Accessed April 21, 2009.
  10. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med. 1994;154:1586–1595
  11. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol. 2003;3:4–11
  12. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103:6682–6687
  13. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol. 1979;57:114–117
  14. Sturino CF, O'Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem. 2007;50:794–806
  15. Paolini JP, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients. Am J Cardiol. 2008;101:625–630
  16. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62:1959–1970
  17. Kush D, Hu D-Y, Ye P, et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology. In press.
  18. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(Suppl):22C–31C
  19. Tatò F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction of serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol. 1998;81:805–807
  20. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 1992;92:77–81
  21. Grundy SM, Vega GL, McGovern ME, et al. Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes—results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568–1576
  22. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA. 2000;284:1263–1270

PII: S1933-2874(09)00195-0

doi: 10.1016/j.jacl.2009.04.048

Journal of Clinical Lipidology
Volume 3, Issue 3 , Pages 179-186 , May 2009

Article Tools

* Image Usage & Resolution